JAK-STAT信号通路与巨噬细胞炎症调控的研究进展

doi:10.3969/j.issn.1004-616x.2020.05.014

[1] 杨昕, 唐哲, 张鹏, 等. JAK/STAT信号通路在肺癌中的研究进展[J]. 中国肺癌杂志, 2019, 22(1):45-51.
[2] 彭长铁. JAK2-STAT3信号通路在缺血性疾病的研究进展[J]. 临床与病理杂志, 2019, 39(1):159-164.
[3] 宋舟, 张立艳, 董海兵, 等. JAK-STAT信号通路研究进展[J]. 中国畜牧兽医, 2012, 39(6):128-132.
[4] 薛翔, 刘红梅, 邵旦兵, 等. JAK/STAT信号通路调节机制的研究进展[J]. 现代生物医学进展, 2015, 15(11):2161-2165.
[5] MATSUKAWA A. STAT proteins in innate immunity during sepsis:lessons from gene knockout mice[J]. Acta Med Okayama, 2007, 61(5):239-245.
[6] 赵璐. IL-6/STAT3信号传导通路及其在肿瘤靶向治疗的研究进展[J]. 中外医学研究, 2012, 10(14):144-146.
[7] NIEHUES H, RÖSLER B, VAN DER KRIEKEN D A, et al. STAT1 gain-of-function compromises skin host defense in the context of IFN-γ signaling[J]. J Allergy Clin Immunol, 2019, 143(4):1626-1629.
[8] SHENG W, YANG F, ZHOU Y, et al. STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation[J]. Cell Res, 2014, 24(12):1387-1402.
[9] 徐毅晖, 杨元生, 陈垦, 等. IL-21/STAT3通路在溃疡性结肠炎小鼠发病中的表达及其意义[J]. 国际医药卫生导报, 2012, 18(22):3235-3238.
[10] D D, SL R, Jr U J, et al. Stat6 regulation of in vivo IL-4 responses[J]. J Immunol, 2000, 164(5):2303-2310.
[11] KAMEZAKI K, SHIMODA K, NUMATA A, et al. The role of Tyk2, Stat1 and Stat4 in LPS-induced endotoxin signals[J]. Int Immunol, 2004, 16(8):1173-1179.
[12] GREENHILL C J, ROSE-JOHN S, FERLIN W, et al. PL1-3 IL-6 Trans-signaling modulates TLR4-dependent inflammatory responses via STAT3[J]. Cytokine, 2010, 52(1/2):3.
[13] HU X, CHEN J, WANG L, et al. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation[J]. J Leukoc Biol, 2007, 82(2):237-243.
[14] YEGANEGI M, LEUNG C G, MARTINS A, et al. Lactobacillus rhamnosus GR-1-induced IL-10 production in human placental trophoblast cells involves activation of JAK/STAT and MAPK pathways[J]. Reprod Sci, 2010, 17(11):1043-1051.
[15] MATSUKAWA A, TAKEDA K, KUDO S, et al. Aberrant inflammation and lethality to septic peritonitis in mice lacking STAT3 in macrophages and neutrophils[J]. J Immunol, 2003, 171(11):6198-6205.
[16] 祝建波, 夏冰, 郭秋莎, 等. STAT6基因多态性与炎症性肠病的相关性研究[C]//中华医学会第七次全国消化病学术会议. 山东济南, 2007.
[17] OHMORI Y, HAMILTON T A. STAT6 is required for the anti-inflammatory activity of interleukin-4 in mouse peritoneal macrophages[J]. J Biol Chem, 1998, 273(44):29202-29209.
[18] LIU Y, ZHANG H, NI R, et al. IL-4R suppresses airway inflammation in bronchial asthma by inhibiting the IL-4/STAT6 pathway[J]. Pulm Pharmacol Ther, 2017, 43:32-38.
[19] JIMéNEZ-GARCíA L, HIGUERAS M á, HERRANZ S, et al. A hispanolone-derived diterpenoid inhibits M2-Macrophage polarization in vitro via JAK/STAT and attenuates chitin induced inflammation in vivo[J]. Biochem Pharmacol, 2018, 154:373-383.
[20] RAHAL O M, WOLFE A R, MANDAL P K, et al. Blocking interleukin (IL)4- and IL13-mediated phosphorylation of STAT6(Tyr641) decreases M2 polarization of macrophages and protects against macrophage-mediated radioresistance of inflammatory breast cancer[J]. Int J Radiat Oncol, 2018, 100(4):1034-1043.
[21] FUKAO T, FRUCHT D M, YAP G, et al. Inducible expression of Stat4 in dendritic cells and macrophages and its critical role in innate and adaptive immune responses[J]. J Immunol, 2001, 166(7):4446-4455.
[22] GOLL G L, KVIEN T K. New-generation JAK inhibitors:how selective can they be?[J]. Lancet, 2018, 391(10139):2477-2478.
[23] BRECCIA M, ANDRIANI A, MONTANARO M, et al. Ruxolitinib in clinical practice for primary and secondary myelofibrosis:an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN[J]. Ann Hematol, 2017, 96(3):387-391.
[24] 王静雅. Ruxolitinib治疗骨髓纤维化的研究进展[J]. 国际输血及血液学杂志, 2013, 36(3):247-250.
[25] O'SHAUGHNESSY J, DEMICHELE A, MA C X, et al. A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation[J]. Breast Cancer Res Treat, 2018, 170(3):547-557.
[26] HARRIS J E, RASHIGHI M, NGUYEN N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)[J]. J Am Acad Dermatol, 2016, 74(2):370-371.
[27] 张春燕, 范小冬, 秦元, 等. JAK抑制剂托法替布治疗类风湿性关节炎效果的Meta分析[J]. 第三军医大学学报, 2018, 40(6):543-550.
[28] 李志铭, 朱颖杰. JAK/STAT通路及其阻断剂AG490在淋巴瘤中的研究进展[J]. 中国肿瘤临床, 2014, 41(19):1221-1224.
[29] 王克明, 王彬, 贺大林. JAK/STAT通路阻断剂AG490的研究现状[J]. 现代泌尿外科杂志, 2003, 8(1):57-59.
[30] HUBBARD J M, GROTHEY A. Napabucasin:an update on the first-in-class cancer stemness inhibitor[J]. Drugs, 2017, 77(10):1091-1103.
[31] 朱丽华, 徐刚, 龚爱华, 等. STAT3抑制剂Stattic对肝癌细胞Bel-7402生长、迁移、侵袭和放射敏感性的影响[J]. 中华放射医学与防护杂志, 2015, 35(6):413-418.
[32] 陈浩, 李七一, 陆曙. 中医药调控JAK/STAT信号通路的研究进展[J]. 中西医结合心脑血管病杂志, 2016, 14(19):2258-2262.
[33] 高玉桥, 苏丹, 张汉辉. 中药干预JAK/STAT信号通路的研究进展[J]. 时珍国医国药, 2018, 29(9):2236-2240.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 75-78,81.
[2]	ZHANG Zihan, LI Li, ZHANG Wenfeng, ZHANG Yanchao, CHEN Huiling, SHI Ming. Effects of triphenyl phosphate ontoxicity and phagocytosis of mouse macrophage RAW264.7 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 269-275.
[3]	MA Shunpeng, WANG Quankai, WANG Miao, SONG Jiayang, WUHAN Baolier, XIE Guangyun, XU Jianning. Long non-coding RNA regulates apoptosis during glycidyl methacrylate-induced malignant transformation of 16HBE cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 1-5,31.
[4]	ZHAO Junwei, HUA Chenfeng, SHANG Pingping, XIE Fuwei, LI Xiang. Induction of oxidative stress by arsenious acid As(Ⅲ) in A549 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 28-31.
[5]	LUO Ji, CHEN Xiaoqing, LI Bing, MA Zhongchun. In vitro cytotoxicity evaluation of tongue depressors with different materials [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 58-61,65.
[6]	. [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 325-328.
[7]	CHEN Zizhuo, XU Yuhang, JIANG Xiaoxu, ZHAO Jiuzhou, ZHU Jingpu, ZHENG Yipeng, WU Haozhi, LI Wenli, WANG Xin, HAI Chunxu, YU Weihua. Inhibition of LPS-induced inflammatory response by butein in bone marrow primary macrophages [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 171-176.
[8]	HUA Chenfeng, ZHAO Junwei, SHANG Pingping, FAN Meijuan, XIE Fuwei, LI Xiang. Induction of cytotoxicity, inflammatory factor release and apoptosis by cigarettes with different tar releases [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 182-186.
[9]	SUN Jiaojiao, CHE Bizhong, LUO Qiulin, ZHAI Bingzhong, XIN Lili. 1,25-(OH)₂D₃ attenuates PM_2.5-induced oxidative stress in HBE cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(2): 92-97.
[10]	CHEN Zizhuo, XU Yuhang, ZHAO Jiuzhou, ZHU Jingpu, ZHENG Yipeng, LI Wenli, WU Haozhi, HAI Chunxu, YU Weihua. Antioxidant and anti-inflammatory effects of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside in macrophages [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(2): 105-111,117.
[11]	WANG Quankai, XIE Guangyun, MA Shunpeng, GUO Haoran, WUHAN Baolier, SONG Jiayang, XU Jianning. Genotoxicity evaluation of glycidyl methacrylate [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(6): 479-482.
[12]	TANG Jiao, YANG Ying, LI Qing, ZHAO Min, YANG Yingfen. In vitro induction of micronuclei by Panax notoginseng extracting solution [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 397-400.
[13]	YAO Jia, LIU Xing, LU Guangyu, ZHU Fangyu, WU Qianqian, LI Xiangming. Screening of chemical mutagens based on RNR3 romoter-regulated red-green fluorescent protein dual signals in yeast cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(4): 276-282.
[14]	. [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 257-260.
[15]	LIAO Nai, LONG Zi, HAI Chunxu, WANG Xin. 2,3,7,8-tetrachlorodibenzo-p-dioxin alone or in combination with high fat diet on glucose and lipid metabolism in mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(2): 111-118.